Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Upadacitinib effector pathways unravelled

Upadacitinib effector pathways unravelled

Presented By
Dr Bram Verstockt, KU Leuven, Belgium
Conference
ECCO 2022
Trial
Phase 2, U-ACHIEVE
Upadacitinib therapy suppresses pathogenic inflammatory pathways and positively affects tissue-resident cells associated with gut barrier function and mucosal repair in participants with ulcerative colitis (UC), according to an analysis of the phase 2b U-ACHIEVE data. In addition, participants who achieved the stringent histo-endoscopic mucosal response (HEMR) endpoint displayed a unique transcriptional modulation of the gut microenvironment. Dr Bram Verstockt (KU Leuven, Belgium) and colleagues aimed to investigate the effect of upadacitinib on the inflamed intestinal microenvironment in patients with UC and link molecular modulations of pathogenic pathways to upadacitinib efficacy outcomes [1]. For this purpose, data was analysed from the placebo, 15 mg, 30 mg, and 45 mg upadacitinib arms of the phase 2b U-ACHIEVE study (NCT02819635). Differential expre...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on